Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ABLYNX (D) : ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 29TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/04/2011 | 06:10pm CET

GHENT, Belgium, 4 January 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, 11 January 2011 at 11.00 a.m. PST / 08.00 p.m. CET.

 

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx's website at www.ablynx.com:
http://www.ablynx.com/. A replay of the webcast will also be available on the Company's website for 30 days following the presentation.

 

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

 

 

About Ablynx

Ablynx:
http://www.ablynx.com/ (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and Alzheimer's disease. Today, the Company has over 25 projects in the pipeline:
http://www.ablynx.com/en/research-development/pipeline/ and there are five Nanobodies in clinical development. In parallel with its internally developed products, Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 250 people. More information can be found on www.ablynx.com:
http://www.ablynx.com/.

 

 

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68

e:  [email protected]:
mailto:[email protected]

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  [email protected] :
mailto:[email protected]%20

 

Complete version of the press release:
http://hugin.info/137912/R/1477060/413118.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE


HUG#1477060


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
12/12 ABLYNX : 12/12/2017 ablynx reports additional clinically important benefits of c..
12/12 ABLYNX : Reports additional clinically important benefits of caplacizumab from i..
12/07 ABLYNX : Will host a webcast to discuss additional data from its phase iii hercu..
11/29 ABLYNX : 29/11/2017 publication in accordance with article 14 of the belgian law..
11/29 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/21 ABLYNX : 21/11/2017 results from the phase iii hercules study of caplacizumab fo..
11/21 ABLYNX : Results from the phase iii hercules study of caplacizumab for the treat..
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
More news
News from SeekingAlpha
12/07 Ablynx to update on Phase 3 study of caplacizumab December 12
11/16 Ablynx NV reports 9M results
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
Financials (€)
Sales 2017 64,7 M
EBIT 2017 -56,2 M
Net income 2017 -73,4 M
Finance 2017 203 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 20,6x
EV / Sales 2018 23,8x
Capitalization 1 536 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 22,9 €
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX90.11%1 805
CELLTRION, INC.--.--%23 756
IQVIA HOLDINGS INC34.41%21 227
INCYTE CORPORATION-2.16%20 346
LONZA GROUP62.09%19 523
ALNYLAM PHARMACEUTICALS, INC.233.49%12 349